Bladder Ca case study: 63-year-old man with history of carcinoma in situ
In this video, Trinity J. Bivalacqua, MD, PhD, presents the case of a 63-year-old man with history of carcinoma in situ found to have low-grade Ta non-muscle invasive bladder cancer.
Image courtesy of Trinity J. Bivalacqua, MD, PhD
Dr. Bivalacqua
In this video, Trinity J. Bivalacqua, MD, PhD, presents the case of a 63-year-old man with history of carcinoma in situ (CIS) found to have low-grade Ta non-muscle invasive bladder cancer. He had persistent positive cytology for high-grade urothelial cancer. He received bacillus Calmette-Guérin more than 12 months previously for CIS. When he returned for a second opinion about management, a cysto biopsy with hexaminolevulinate (HAL [Cysview]). was recommended. HAL was able to identify CIS, which was only visible on blue light cystoscopy. The patient is now receiving induction BCG. Dr. Bivalacqua is the R. Christian B. Evensen Professor, director of urologic oncology, and associate professor of urology, surgery, and oncology at Johns Hopkins School of Medicine, Baltimore.
Dr. Bivalacqua conducts clinical trials for Taris Biomedical, Photocure, FKD Therapies Oy, NCI, Genentech, and Tissuegenesis. He is a consultant for Photocure.
(Video courtesy of Trinity J. Bivalacqua, MD, PhD)
More videos:
In-office andrology: Videos show office-based hydrocelectomy, vasectomy reversal
Urologists illustrate key steps in management of duct obstruction
Cord denervation: Surgeons describe microsurgical techniques in men with scrotal pain
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
